Immunohistochemical Expression of Nkx3.1 in Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia at a Tertiary Care Hospital in Karachi
DOI:
https://doi.org/10.37762/jgmds.10-4.501Keywords:
Adenocarcinoma prostate, NKX3.1, Benign prostate hyperplasia, ImmunohistochemistryAbstract
OBJECTIVES
To determine NKX3.1 expression in prostatic adenocarcinoma and benign prostate hyperplasia on Immunohistochemistry at a tertiary care hospital in Karachi.
METHODOLOGY
74 prostatic specimens were recruited in this comparative cross-sectional study at the Department of Pathology, Pakistan Navy Station Shifa Hospital, Karachi, from January 2018 to February 2019. Of these, 37 specimens were of prostatic adenocarcinoma, and 37 were benign prostate hyperplasia. All specimens were subjected to immunohistochemical staining with NKX3.1. Statistical analysis was done by using SPSS version 23.0. The association of the extent of NKX3.1 staining between the adenocarcinoma and hyperplasia group was assessed using the Chi-square test x2.
RESULTS
Of the 37 cases of benign prostatic hyperplasia subjected to NKX3.1 staining, 32 showed positive staining with strong to moderate intensity. No staining was observed in 5 cases. 37 cases of adenocarcinoma prostate stained for NKX3.1 revealed positive staining in 30 cases with strong to moderate intensity. Negative staining was seen in 7 cases. The prostatic adenocarcinoma showed a statistically significant association of NKX3.1 positivity compared to benign prostatic hyperplasia cases. The p-value was found to be 0.03.
CONCLUSION
NKX3.1 staining was highly specific for prostate epithelium, as it was positive in most cases. This immune marker was useful for distinguishing prostatic origin in the context of metastatic lesions. Adding NKX3.1 protein staining to a panel of features may add value to the diagnosis if applied in the appropriate clinicopathologic context.
Downloads
Metrics
References
Rawla P. Epidemiology of prostate cancer. World J Oncol.2019;10(2):63–89. Av
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018;68(6):394–424
Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J Surg Oncol.2018;16(1)
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol.2021;4(6):877–92
Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. Risk of prostate cancer associated with familial and hereditary cancer syndromes. J Clin Oncol.2020;38(16):1807–13
Zhang F, Xu J, Sun C, Dai F, Zhu Q, Liang H. A scientometric visualization analysis for benign prostatic hyperplasia from 2016 to 2022. Urol Int.2023;107(2):111–25
Descotes J-L. Diagnosis of prostate cancer. Asian J Urol.2019;6(2):129–36
Nomani BH, Alamgir M. Diagnostic utility of various biomarkers for prostate cancer: A review. J Bahria Univ Med Dent Coll.2019;09(02):151–5
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. De Marzo AM. NKX3. 1 as a marker of prostatic origin in metastatic tumors. The American journal of surgical pathology. 2010;34
Asatiani E, Huang WX, Wang A, Ortner R, Cavalli E, Haddad LR, et al. Deletion, methylation, and expression of the NKX3. 1 suppressor gene in primary human prostate cancer. Cancer research. 2005;65:1164–73
Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al. Abate-Shen C. Roles for Nkx3. 1 in prostate development and cancer. Genes & development. 1999;13(8):966–77
Fatima A, Mushtaq S, Loya A. Expression of NKX 3.1 in Sertoli Cell Tumors. Pakistan Armed Forces Medical Journal. 2022;72:1965–8
Carneiro A, Barbosa ÁRG, Takemura LS, Kayano PP, Moran NKS, Chen CK, et al. The role of immunohistochemical analysis as a tool for the diagnosis, prognostic evaluation and treatment of prostate cancer: A systematic review of the literature. Front Oncol.2018;8:377
Tariq H, Ahmed R, Afzal S, Hashmi SN, Hamdani SN. Immunohistochemical expression of alpha methylacyl-coa racemase (amacr) in carcinoma prostate in Pakistani population. Pakistan Armed Forces Medical Journal (PAFMJ). 2017;67(6):1054–7.
Nisar B, Sarwar N, Sharif S, Hameed A, Naz S. Expression of p63 protein to differentiate benign prostatic hyperplasia and carcinoma of prostate in Pakistani population. Ann King Edw Med Univ.2017;23(2).
Ahmed EIBDS, Mahjaf GM, Hamad MNM, editors Immunohistochemical Expression of NKX3. 1 in Prostatic Adenocarcinoma Correlates with Tumors Grade among Sudanese. SAR J Pathol Microbiol. 2023;4(3)
Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3. 1 expression in human prostate cancers correlates with tumor progression1, 2. Cancer research. 2000;60:6111–5
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. NKX3. 1 as a marker of prostatic origin in metastatic tumors. The American journal of surgical pathology. 2010;34(8):1097–105
Irer B, Toylu A, Aslan G, Celebi I, Yorukoglu K, Atabey N. Increased expression of NKX3. 1 in benign prostatic hyperplasia. Urology. 2009;73(5):1140–4
Atta IS. NKX3. 1 versus cyclin D1 expression in prostatic adenocarcinoma: a comparative study. Egyptian Journal of Pathology. 2017;37(2):306–14
Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: The Nkx3. 1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation. 2008;76(6):717–27
Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol.2002;22(5):1495–503
Chuang A-Y, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol.2007;31(8):1246–55
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Beenish Hussain
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
